ArticleJournal of neurology2025
A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisease-modifying therapies (DMTs) have significantly improved the management of multiple sclerosis (MS), but their potential nervous system adverse events (AEs) remain a critical concern. This study aims to evaluate the risk of nervous system AEs associated with 11 DMTs using the FDA Adverse Event Reporting System (FAERS) database, following the READUS-PV guidelines.
methodsWe performed a disproportionality analysis on FAERS data from Q1 2004 to Q3 2024, focusing on nervous system AEs related to DMTs, such as Alemtuzumab (AL), Ofatumumab (OF), Ocrelizumab (OC), and Fingolimod (FI). Using disproportionality analysis and Bayesian methods, we identified signals of these AEs. We also conducted subgroup analyses across age, gender, weight, geographic regions, and outcomes to assess AE distribution. In addition, a sensitivity analysis was done to evaluate the consistency of the association between DMTs and nervous system AEs across severities. The time to onset and clinical characteristics of AEs were examined as well.
resultsAmong 245,469 nervous system AE reports, Siponimod (SI), Natalizumab (NA), FI, and Teriflunomide (TE) exhibited the highest signal values (ROR > 3.0), with SI showing the strongest association [ROR = 3.44, 95% CI (3.34-3.55)]. Females accounted for 76.0% of nervous system AEs, and severe AEs such as central nervous system lesions (mortality rate: 0.97%) and cognitive disorders (mortality rate: 0.94%) were detected. The median time to onset of AEs varied significantly across DMTs, ranging from 14 days for AL to 816 days for Interferon Beta-1a (IN). Subgroup analyses highlighted variations in AE reporting across different demographics and geographic regions. The sensitivity analysis further confirmed the robustness of our findings, indicating consistent associations between DMTs and severe nervous system AEs.
conclusionsThis study highlights significant differences in the nervous system AEs profiles of DMTs, with SI, NA, FI, and TE showing higher risks of nervous system AEs. These findings underscore the importance of vigilant monitoring and personalized treatment strategies to mitigate nervous system risks in MS patients. Further research is needed to confirm these associations and investigate the mechanisms that underlie them.
Indexed as
Identifiers
40465056What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.